^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lymphoma
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Pfizer Press Release
    Title:

    FDA ACCEPTS SUPPLEMENTAL NEW DRUG APPLICATION FOR PFIZER’S XALKORI® (CRIZOTINIB) FOR THE TREATMENT OF PEDIATRIC ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA

    Published date:
    09/23/2020
    Excerpt:
    Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to the Company’s supplemental New Drug Application(sNDA)for XALKORI® (crizotinib) for the treatment of pediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK)-positive.
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non-Hodgkin’s Lymphoma)
    New
    Excerpt:
    XALKORI is a kinase inhibitor indicated for the treatment of…pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive.
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Natl Cancer Inst
    Title:

    Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients

    Excerpt:
    Crizotinib exerted a potent antitumor activity with durable responses in advanced, heavily pretreated ALK+ lymphoma patients, with a benign safety profile.
    DOI:
    10.1093/jnci/djt378